Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Licenses Targets Resulting from Galapagos Collaboration

NEW YORK, Jan. 20 (GenomeWeb News) - Boehringer Ingelheim has licensed a number of potential antiviral targets from Galapagos Genomics after identifying them using Galapagos' gene knock-down technology, Galapagos said yesterday.

 

Scientists at Boehringer's virology research center in Laval, Canada, used Galapagos' SilenceSelect platform, a collection of adenoviruses with siRNA knock-down sequences targeting over 3,000 human transcripts, to identify a number of genes that influence viral replication in human cells.

 

As part of the two companies' technology agreement from October 2003, Galapagos, which is based in the Netherlandsand Belgium, will obtain a milestone payment from Boehringer for licensing the targets.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.